Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 8, 2016, Pages 1007-1012

  Vercellino, Marco ^a   Fenoglio, Chiara ^b   Galimberti, Daniela ^b   Mattioda, Alessandra ^a   Chiavazza, Carlotta ^a   Binello, Eleonora ^a   Pinessi, Lorenzo ^a   Giobbe, Dario ^a   Scarpini, Elio ^b   Cavalla, Paola ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

disability; genetic; inflammation; Multiple sclerosis; neuroprotection; progranulin; relapse

Indexed keywords

PROGRANULIN; GRN PROTEIN, HUMAN; SIGNAL PEPTIDE; METHYLPREDNISOLONE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GRN GENE; HETEROZYGOTE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS SEVERITY SCORE; ONSET AGE; PROTEIN BLOOD LEVEL; RATING SCALE; RELAPSE; BLOOD; CLINICAL TRIAL; CONVALESCENCE; DISEASE EXACERBATION; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; PHENOTYPE; PREDICTIVE VALUE; RECURRENT DISEASE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC VARIABILITY;

ADULT; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RECOVERY OF FUNCTION; RECURRENCE; RISK FACTORS;

EID: 84978127615     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515610646     Document Type: Article

References (17)

1. Ahmed Z, Mackenzie IR, Hutton ML, et al. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007; 4 (7): 1-13.
2. Van Damme P, Van Hoecke A, Lambrechts D, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 2008; 181: 37-41.
3. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442: 916-919.
4. Rademakers R, Eriksen JL, Baker M, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP-43-positive frontotemporal dementia. Hum Mol Genet 2008; 17: 3631-3642.
5. Galimberti D, Fenoglio C, Cortini F, et al. GRN variability contributes to sporadic frontotemporal lobar degeneration. J Alzheimers Dis 2010; 19: 171-177.
6. Fenoglio C, Galimberti D, Cortini F, et al. Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. J Alzheimers Dis 2009; 18: 603-612.
7. Sleegers K, Brouwers N, Maurer-Stroh S, et al. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology 2008; 71: 253-259.
8. Vercellino M, Grifoni S, Romagnolo A, et al. Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. Mult Scler 2011; 17: 1194-1201.
9. Galimberti D, Dell'Osso B, Altamura AC, et al. Psychiatric symptoms in frontotemporal dementia: epidemiology, phenotypes, and differential diagnosis. Biol Psychiatry. Epub ahead of print 8 2015. DOI: 10.1016/j.biopsych.2015.03.028.
10. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-2712.
11. Vercellino M, Plano F, Votta B, et al. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005; 64: 1101-1107.
12. Fenoglio C, Scalabrini D, Esposito F, et al. Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. Genes Immun 2010; 11: 497-503.
13. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
14. Vercellino M, Romagnolo A, Mattioda A, et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand 2009; 119: 126-130.
15. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57: 289-300.
16. Yin F, Banerjee R, Thomas B, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med 2010; 207: 117-128, S1-S4.
17. Hohlfeld R,. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis? J Neurol Sci 2008; 265: 93-96.